🟦 Non-Member Event : PARTNERS – Basic Partners Program for Social Workers
Date: May 19th - 21st Location: Indianapolis, IN
All members have the option of attending our various HTC-centric events which include:
Date: May 19th - 21st Location: Indianapolis, IN
Date: June 21st - 25th Location: Washington, DC
Date: Thursday, June 26th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Washington Update SESSION OBJECTIVE: Come to hear the latest on actions in Washington that could impact your HTC and your patients – from 340B reform and federal funding for hemophilia programs, to Congress’ “One Big Beautiful Bill” and how it could Read the full article...
Date: July 16th - 17th Location: Indianapolis, IN
Date: Tuesday, July 22nd, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Review the clinical benefits of wilate®, highlighting the benefits vs current vWD therapies. OBJECTIVES: Understand the attributes of wilate® for vWD: 1:1 ratio which mimics the physiologic activity of vWF and FVIII and the synchronous decay curves, which facilitates Read the full article...
Date: Tuesday, August 12th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Big Bill, Big Insurance Impact - What do HTCs need to know now about coming health insurance changes and how to prepare? SESSION OBJECTIVE: The One Big Beautiful Bill Act and other Washington policies are reshaping the insurance landscape for HTCs Read the full article...
Date: August 21st - 23rd Location: Denver, CO
Date: Wednesday, August 27th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TITLE: Juggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. OBJECTIVES: To educate attendees on challenges, shared decision making in hemophilia and introduce Read the full article...
Date: Thursday, September 4th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence, Patient Perspective & Contract Opportunities. OBJECTIVES: Explore updates to HEM Alliance member contract terms and the associated provider economics. Review the latest clinical data updates, describing the long-term efficacy and safety of Read the full article...
Date: Wednesday, September 10th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TITLE: Mental Health and Substance Use in the Bleeding Disorders Community. DESCRIPTION: The bleeding disorders community does not have the same access to inpatient and residential mental health and substance use treatment that the general population does. This webinar will Read the full article...
Date: Wednesday, September 17th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Qfitlia Overview: Clinical, Access, and Distribution Dynamics. OBJECTIVE: Dr. Lynn Malec will review key elements of the Qfitlia efficacy and safety profile and Adam Gurry, Sanofi Director of Access Strategy, will provide insights on the Qfitlia access and distribution strategy. Read the full article...
Date: Wednesday, October 1st, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: On-demand and Surgical Use of ADVATE® OBJECTIVE: This session will explore critical aspects of hemophilia A management, focusing on the unique role of ADVATE in on-demand and perioperative settings. AUDIENCE: All HTC Staff. SPEAKER: Jessica Grandoni, Pharm.D., BCPS, was the Read the full article...
Date: October 5 - 7, 2025 Location: Washington, DC Agenda Overview Sunday, October 5th – Networking Reception 6:30pm - 8:30pm Monday, October 6th – Breakfast at 7:30am, followed by Meeting 8:30am - 6:30pm, to include our Hill Day Training and Dinner to follow Tuesday, October 7th – Breakfast then Hill Day (schedules TBD) Read the full article...
Date: Wednesday, October 15th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Prophylaxis in VWD: Iron as a Metric of Success at Healing. WEBINAR SUMMARY: A presentation on rethinking prophylaxis in VWD through a lens of healing and iron status. This presentation explores a multidimensional approach to bleeding disorders, with a focus on Read the full article...
Date: Thursday, October 23rd, 2025 Time: 3:00pm - 4:00pm ET WEBINAR TITLE: Revolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A. DESCRIPTION: Please join us for an engaging discussion featuring nurses Jennifer Maahs, RN, PNP, MSN and Joseph Stanco, MSN, DNP, CCRC as they share Read the full article...
Date: Thursday, October 30th, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia. OBJECTIVE: To provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors, and supporting data from the explorer8 trial. AUDIENCE: Read the full article...
Date: Thursday, November 6th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: Jivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years. OBJECTIVE: This session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data Read the full article...
Date: Wednesday, November 12th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: VONVENDI® Approved for Adults and Pediatric Patients. OBJECTIVE: Understand the underlying mechanism of VWD and the role of VWF. Review unmet needs in the treatment of VWD. Identify the unique characteristics of VONVENDI as the first and only recombinant treatment Read the full article...
Date: Thursday, November 13th, 2025 Time: 1:00pm - 2:00pm ET WEBINAR TOPIC: The HEMGENIX Toolkit OBJECTIVE: Overview of the tools and resources available to treatment centers to help support patients eligible and interested in HEMGENIX AUDIENCE: All HTC Staff. SPEAKER: Bonnie Ben-Shmuel Bonnie Ben-Shmuel is a seasoned biopharmaceutical marketing leader with Read the full article...
Date: Wednesday, December 3rd, 2025 Time: 2:00pm - 3:00pm ET WEBINAR TOPIC: Translating Evidence into Practice: Real-World Patient Cases with ALTUVIIIO. OBJECTIVE: This session will bring together clinical evidence and real-world experience to illustrate how ALTUVIIIO can optimize treatment and improve outcomes for patients living with Hemophilia A. AUDIENCE: All HTC Staff. Read the full article...